Lobe Sciences Invites You to Join Us at the Q4 Virtual Investor Summit

November 8, 2021

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - Lobe Sciences (OTC Pink: GTSIF) today announced that Philip Young, CEO & Director will be attending the Q4 Virtual Investor Summit. Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Our goal is to change that fact, and during this presentation, Philip Young, CEO & Director, will outline a path for the development of therapeutics for which Lobe Sciences intends to seek FDA approval in the United States, and similar approvals internationally.

Event:Q4 Investor SummitDate:November 16-17th, 2021Presentation:November 17th at 11:00 AM ETLocation:https://us06web.zoom.us/webinar/register/WN_ecoTV7Y1Rmmfr_5yjDFvXQ

About Lobe Sciences

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information:

Lobe Sciences
Philip Young
(949) 505-5623

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.